Galapagos (GLPG) Receives a Hold from Stifel Nicolaus
In a report released today, Derek Archila from Stifel Nicolaus reiterated a Hold rating on Galapagos (GLPG). The company’s shares closed last Friday at $138.19, close to its 52-week low of $112.00.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 8.4% and a 44.5% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.
Currently, the analyst consensus on Galapagos is a Hold with an average price target of $161.74, representing a 19.6% upside. In a report issued on September 11, Raymond James also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
Galapagos’ market cap is currently $8.66B and has a P/E ratio of 90.70. The company has a Price to Book ratio of 2.92.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Read More on GLPG: